Programs
- M. Tech. in Automotive Engineering -
- Clinical Fellowship in Laboratory Genetics & Genomics - Fellowship
Publication Type : Journal Article
Publisher : Med. Chem. Commun
Source : Med. Chem. Commun., The Royal Society of Chemistry, Volume 10, p.2024-2037 (2019)
Url : http://dx.doi.org/10.1039/C9MD00165D
Campus : Amritapuri
School : School of Biotechnology
Department : biotechnology
Year : 2019
Abstract : Members of the matrix metalloproteinase (MMP) family have biological functions that are central to human health and disease, and MMP inhibitors have been investigated for the treatment of cardiovascular disease, cancer and neurodegenerative disorders. The outcomes of initial clinical trials with the first generation of MMP inhibitors proved disappointing. However, our growing understanding of the complexities of the MMP function in disease, and an increased understanding of MMP protein architecture and control of activity now provide new opportunities and avenues to develop MMP-focused therapies. Natural products that affect MMP activities have been of strong interest as templates for drug discovery, and for their use as chemical tools to help delineate the roles of MMPs that still remain to be defined. Herein, we highlight the most recent discoveries of structurally diverse natural product inhibitors to these proteases.
Cite this Research Publication : Dr. Geetha Kumar, Dr. Bipin G. Nair, J. Perry, J. P., and Martin, D. B. C., “Recent insights into natural product inhibitors of matrix metalloproteinases”, Med. Chem. Commun., vol. 10, pp. 2024-2037, 2019